Gelteq to Launch Human Clinical Trials Next Quarter, Expands Pipeline into Diabetes and Peptides
GELS has more than doubled off its 52-week low of $0.387.
Summary
Gelteq announced plans to commence human clinical trials next quarter, alongside starting a preclinical diabetes study and expanding its pipeline into peptide-based therapeutics. This comprehensive update builds on recent milestones including securing $3.5 million in debt financing, commencing an antiparasitic veterinary trial, and establishing a China Center of Excellence. For a microcap biotech, initiating human trial planning and diversifying into major chronic disease categories like diabetes significantly advances its proprietary drug delivery platform and future market potential. Human clinical trials are expected to begin in Q3 2026.
At the time of this announcement, GELS was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.39 to $2.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.